Last reviewed · How we verify

Local Standard of Care

Istituto Oncologico Veneto IRCCS · FDA-approved active Small molecule

Local Standard of Care is a Small molecule drug developed by Istituto Oncologico Veneto IRCCS. It is currently FDA-approved for Various cancers as per institutional standard treatment protocols. Also known as: SoC, Hydroxycarbamide, Bevacizumab, Sunitinib.

Local Standard of Care refers to the established treatment protocols and therapeutic approaches used at Istituto Oncologico Veneto IRCCS for cancer management, which vary by tumor type and patient characteristics.

Local Standard of Care refers to the established treatment protocols and therapeutic approaches used at Istituto Oncologico Veneto IRCCS for their patient population, rather than a single defined drug entity. Used for Variable depending on trial context; typically cancer types treated at Istituto Oncologico Veneto IRCCS.

At a glance

Generic nameLocal Standard of Care
Also known asSoC, Hydroxycarbamide, Bevacizumab, Sunitinib, Octreotide (Sandostatin LAR)
SponsorIstituto Oncologico Veneto IRCCS
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

This is not a single drug entity but rather a comparator arm representing the institutional standard treatment regimen. It typically includes conventional chemotherapy, targeted therapy, immunotherapy, or combinations thereof based on current clinical guidelines and institutional practice for the specific cancer type being studied.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Local Standard of Care

What is Local Standard of Care?

Local Standard of Care is a Small molecule drug developed by Istituto Oncologico Veneto IRCCS, indicated for Various cancers as per institutional standard treatment protocols.

How does Local Standard of Care work?

Local Standard of Care refers to the established treatment protocols and therapeutic approaches used at Istituto Oncologico Veneto IRCCS for cancer management, which vary by tumor type and patient characteristics.

What is Local Standard of Care used for?

Local Standard of Care is indicated for Various cancers as per institutional standard treatment protocols.

Who makes Local Standard of Care?

Local Standard of Care is developed and marketed by Istituto Oncologico Veneto IRCCS (see full Istituto Oncologico Veneto IRCCS pipeline at /company/istituto-oncologico-veneto-irccs).

Is Local Standard of Care also known as anything else?

Local Standard of Care is also known as SoC, Hydroxycarbamide, Bevacizumab, Sunitinib, Octreotide (Sandostatin LAR).

What development phase is Local Standard of Care in?

Local Standard of Care is FDA-approved (marketed).

Related